Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome (II) plus nab-paclitaxel and gemcitabine vs nab-paclitaxel and gemcitabine for first-line treatment of advanced pancreatic cancer
ChiCTR2400090861Phase 4Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Oct 2024
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of irinotecan liposome in pancreatic adenocarcinoma (PDAC), pancreatic cancer (PC) and pancreatic cancer (PDAC) (4 arms), sponsored by Harbin Medical University Cancer Hospital. Primary endpoints: RP2D and ORR. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
irinotecan liposome
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)pancreatic cancer (PDAC)
Beyond the preview
Go deeper on ChiCTR2400090861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090861.